Rare Endocrine Disorders
Pharmacotherapies
Explore facts and recommendations for pharmacological treatments for rare endocrine disorders.
We didn't find any resources that match your selection.
Please adjust your filter(s) and try again.
Somapacitan vs. Once-daily Growth Hormone - Phase 3 Pediatric Patients with Growth Hormone Deficiency (REAL 4)
This video discusses the REAL4 trial, the pivotal Phase 3 trial investigating efficacy and safety of once-weekly somapacitan compared to once daily growth hormone (GH) in growth-hormone-naïve pre-pubertal children with GH deficiency.
Somapacitan vs. Once-daily Growth Hormone - Phase 3 Pediatric Patients with Growth Hormone Deficiency (REAL 4)
Results of REAL 4, the pivotal Phase 3 trial investigating efficacy and safety of once-weekly somapacitan compared to once daily growth hormone (GH) in growth-hormone-naïve pre-pubertal children with GH deficiency.
Somapacitan Mechanism of Action
This video discusses the mechanism of action of somapacitan.
Somapacitan vs. Once-daily Growth Hormone - Phase 2 Pediatric Patients with Growth Hormone Deficiency (REAL 3)
Overview of REAL 3, the Phase 2 dose-finding trial investigating efficacy and safety of once-weekly somapacitan compared to once daily growth hormone (GH) injection in growth-hormone naïve pre-pubertal children with GH deficiency.
Somapacitan Treatment-naive Adults with Growth Hormone Deficiency (REAL 1)
Summary of REAL 1, the pivotal Phase 3 study evaluating the efficacy and safety of once-weekly somapacitan compared to once-weekly placebo or once-daily growth hormone in adults with growth hormone deficiency.
Albumin Interactions with Somapacitan
An overview of expected albumin interactions from hypoalbuminemia or other protein-bound drugs based on the mechanism of protraction (albumin-binding) used by somapacitan.
Find more information
Find product information
Explore our portfolio of products for treating rare endocrine disorders, including prescribing information, safety data sheets, and storage and stability information.
Continuing education
Explore accredited rare endocrine disorders education opportunities supported by Novo Nordisk and provided by third-party organizations.
The purpose of this site is to provide relevant medical and scientific information about Novo Nordisk products and areas of therapeutic interest. Information about investigational products or investigational uses of approved products neither implies FDA approval for these products or uses, nor establishes the safety or efficacy of these products or uses. There is no guarantee that any investigational product or investigational use will receive FDA approval or become commercially available in the United States. Novo Nordisk does not recommend or suggest use of its products in any manner inconsistent with FDA-approved labeling.
This site is intended for United States healthcare professionals only. The information on this site—including all product information—pertains to residents of the United States only. Any products referenced on this site may have different labelling in different countries.
